India to Singapore: Arishta Export Trade Route

Importing Arishta formulations into Singapore necessitates obtaining a CPM product listing from the HSA. This listing is a prerequisite for the import, manufacture, or assembly of CPMs within the country. The applicant must be a locally registered company with the Accounting and Corporate Regulatory Authority (ACRA) and is responsible for ensuring the safety and quality of the CPM in the market. (hsa.gov.sg)

The application process involves submitting a comprehensive dossier that includes:

• Product Information: Details such as product name, dosage form, active ingredients, indications, dosage, and directions for use.

• Manufacturing Details: Information about the manufacturing site, including compliance with Good Manufacturing Practice (GMP) standards.

• Quality Control Measures: Documentation of quality control tests, stability studies, and adherence to permissible limits for toxic heavy metals and microbial content.

While specific timelines for approval are not publicly detailed, applicants should anticipate a thorough evaluation process. Product registration fees are applicable, though exact amounts are not specified in the available information.

Indian manufacturers exporting Arishta formulations to Singapore must adhere to stringent GMP standards. The HSA mandates compliance with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice for Medicinal Products. This guide ensures that products are consistently produced and controlled to quality standards appropriate for their intended use. (hsa.gov.sg)

Overseas manufacturers are required to provide evidence of GMP compliance. Acceptable forms of evidence include a valid GMP certificate issued by a PIC/S member authority or a valid GMP inspection report. If such evidence is not available, the HSA may conduct an on-site GMP inspection to assess compliance. (hsa.gov.sg)

As of March 2026, specific details regarding Indian facilities currently approved or recent inspections by the HSA are not publicly disclosed. Manufacturers are advised to maintain up-to-date GMP certifications and be prepared for potential inspections to ensure compliance with Singapore's regulatory standards.

In December 2023, the HSA revised its Guidance Notes on Good Distribution Practice (GDP) to clarify requirements for handling Active Ingredients under the new Health Products (Active Ingredients) Regulations 2023. This revision primarily impacts importers and wholesalers, emphasizing the need for a robust quality system to ensure products are consistently stored and handled under appropriate conditions. (hsa.gov.sg)

Additionally, with effect from 25 March 2026, the HSA will issue verifiable electronic certificates for exporters, including the Certificate of a Pharmaceutical Product and Free Sale Certificate, using GovTech’s FileSG digital platform. This transition aims to streamline the certification process and enhance document verification. (hsa.gov.sg)

These developments underscore Singapore's commitment to maintaining high regulatory standards and adapting to technological advancements in pharmaceutical regulation.

Arishta formulations, traditional Ayurvedic medicinal products, have a niche presence in Singapore's healthcare market. While specific market size data for Arishta formulations is not readily available, the broader herbal and traditional medicine sector has been experiencing growth. This trend is driven by increasing consumer interest in natural and holistic health solutions, an aging population seeking alternative therapies, and a rise in disposable income allowing for diversified healthcare spending. Singapore's universal health coverage and emphasis on integrative medicine further support the demand for such products. The majority of Arishta formulations are imported, primarily from India, with limited domestic production due to the specialized nature of these products.

Singapore maintains a 0% Most-Favored-Nation (MFN) import duty rate for pharmaceutical products classified under HS code 30049011, which includes finished pharmaceutical formulations containing Arishta. Additionally, the India-Singapore Comprehensive Economic Cooperation Agreement (CECA) ensures that pharmaceutical imports from India benefit from this 0% import duty rate. Singapore imposes a Goods and Services Tax (GST) of 7% on all imports, including pharmaceuticals. There are no anti-dumping duties or additional charges specific to pharmaceutical imports under this HS code.

India is the primary supplier of Arishta formulations to Singapore, accounting for 1.8% of India's total Arishta formulation exports, valued at $1.4 million. Other countries supplying similar herbal medicinal products include China and various European Union (EU) nations. India's pricing for Arishta formulations is generally competitive, often lower than that of EU manufacturers due to lower production costs and economies of scale. Chinese herbal products may offer competitive pricing; however, Indian Arishta formulations benefit from established trust and recognition in the Singaporean market, particularly among consumers familiar with Ayurvedic medicine.

India has solidified its position as a global leader in the pharmaceutical industry, particularly in the production of generic medicines. As of 2024, the country meets 20% of global demand for generic drugs, including 40% of the United States' generic drug needs and 25% of the United Kingdom's market. This extensive reach underscores India's capability to supply high-quality pharmaceutical formulations, including those containing Arishta.

The nation's manufacturing prowess is supported by a vast network of facilities adhering to stringent international standards. By 2024, India had surpassed the United States in the number of FDA-registered generic manufacturing sites, boasting 752 FDA-approved plants. Additionally, there were 2,050 facilities certified by the World Health Organization's Good Manufacturing Practices (WHO-GMP) and 286 approved by the European Directorate for the Quality of Medicines (EDQM). This extensive infrastructure ensures the production of finished dosage forms, such as tablets, capsules, and syrups containing Arishta, that meet global quality benchmarks.

Cost efficiency remains a cornerstone of India's pharmaceutical industry. The country's ability to produce affordable medicines is attributed to factors like competitive land rates, low resource expenses, and affordable machinery costs. These advantages enable Indian manufacturers to offer Arishta formulations at prices that are competitive on the global stage.

When evaluating the sourcing of Arishta formulations, it's essential to consider cost, quality, and regulatory acceptance.

• Cost: India's pharmaceutical industry is renowned for its cost-effective production methods. The country's generic drug manufacturing market was valued at USD 28.07 billion in 2024 and is projected to reach USD 51.61 billion by 2033, growing at a CAGR of 7.00% from 2025 to 2033. This growth reflects India's ability to produce affordable medicines. In contrast, the European Union (EU) often has higher production costs due to stringent regulations and higher labor expenses. China, while also a significant player in generic formulations, faces challenges related to quality perception and regulatory compliance.

• Quality Perception: India's pharmaceutical sector has gained global recognition for manufacturing high-quality generic drugs. The country's commitment to research and development, along with its emphasis on high-quality generic medications, has reinforced its status in the global pharmaceutical market. The EU is also known for high-quality pharmaceutical products, but at a higher cost. China has made strides in improving quality but still faces skepticism in certain markets.

• Regulatory Acceptance in Singapore: Singapore's Health Sciences Authority (HSA) recognizes and accepts pharmaceutical products from countries with stringent regulatory environments. India's numerous FDA-approved and WHO-GMP-certified facilities align with Singapore's regulatory standards, facilitating smoother import processes. The EU's stringent regulations are also well-regarded, while Chinese products may undergo more rigorous scrutiny due to past quality concerns.

• Supply Reliability Track Record: India has established itself as a reliable supplier of generic medicines, exporting pharmaceuticals to over 200 countries. The country's extensive manufacturing infrastructure and experience in global supply chains contribute to its dependability. The EU maintains a strong track record but at higher costs, while China's reliability has improved but still faces occasional challenges.

India's pharmaceutical industry demonstrates robust manufacturing capacity for finished dosage forms, including formulations containing Arishta. The country hosts over 500 active pharmaceutical ingredient (API) producers, accounting for approximately 8% of the global API market. This extensive network supports the production of various dosage forms, such as tablets, capsules, syrups, and injections.

Packaging and cold chain capabilities in India have seen significant advancements. The country's commitment to research and development, along with its emphasis on high-quality generic medications, has reinforced its status in the global pharmaceutical market. These advancements ensure that Arishta formulations are packaged and transported under optimal conditions, maintaining their efficacy and safety.

Regarding regulatory compliance, Indian manufacturers have a strong track record. The country has the highest number of pharmaceutical manufacturing facilities compliant with US FDA standards and hosts over 500 API producers. This compliance ensures that Arishta formulations meet international quality standards.

As of March 2025, there have been no significant supply disruptions reported in the India-Singapore pharmaceutical trade route. Indian manufacturers continue to expand their capacities to meet growing global demand. For instance, Aragen Life Sciences commissioned a state-of-the-art formulations manufacturing facility in Hyderabad in October 2023, enhancing its ability to produce a wide range of dosage forms.

For Singapore buyers aiming to source Arishta formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Arishta formulations.

• Minimum Order Quantities (MOQs): Indian manufacturers typically have flexible MOQs, accommodating both small and large orders. However, it's advisable to confirm specific MOQs with each supplier to align with procurement needs.

• Payment Terms: Common payment terms in India-Singapore pharmaceutical trade include Letters of Credit (LC) and Telegraphic Transfers (TT). Negotiating favorable terms, such as partial advance payments with balance upon delivery, can be beneficial.

• Supplier Qualification Process: Conduct thorough due diligence by reviewing manufacturers' certifications (e.g., FDA, WHO-GMP), inspecting facilities if possible, and assessing their compliance with Singapore's regulatory requirements.

• Regulatory Compliance: Ensure that the selected Indian manufacturers have a history of compliance with international standards and have not faced significant regulatory actions. This can be verified through regulatory databases and audit reports.

By implementing these strategies, Singapore buyers can establish a reliable and cost-effective supply chain for Arishta formulations from India.

By meticulously following this comprehensive supplier qualification framework, Singapore companies can ensure that their Indian Arishta suppliers meet the highest standards of quality and regulatory compliance, thereby safeguarding public health and maintaining market integrity.